Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here are three stocks where the outlook is warranted and some alternatives with better fundamentals.
Movado (MOV)
Consensus Price Target: $30.75 (5.7% implied return)
With its watches displayed in 20 museums around the world, Movado (NYSE:MOV) is a watchmaking company with a portfolio of watch brands and accessories.
Why Are We Out on MOV?
- Muted 5.8% annual revenue growth over the last five years shows its demand lagged behind its consumer discretionary peers
- Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 3.3% for the last two years
- Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
Movado is trading at $29.10 per share, or 18.9x forward P/E. Check out our free in-depth research report to learn more about why MOV doesn’t pass our bar.
Royalty Pharma (RPRX)
Consensus Price Target: $52.44 (7% implied return)
Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself.
Why Does RPRX Fall Short?
- Flat sales over the last two years suggest it must find different ways to grow during this cycle
- Revenue base of $2.38 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
At $49.00 per share, Royalty Pharma trades at 9.4x forward P/E. Dive into our free research report to see why there are better opportunities than RPRX.
Cisco (CSCO)
Consensus Price Target: $89.09 (-0.8% implied return)
Founded in 1984 by a husband and wife team who wanted computers at Stanford to talk to computers at UC Berkeley, Cisco (NASDAQ:CSCO) designs and sells networking equipment, security solutions, and collaboration tools that help businesses connect their systems and secure their digital operations.
Why Are We Hesitant About CSCO?
- Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 1.6% over the last two years was below our standards for the business services sector
- 5.9 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
- Waning returns on capital imply its previous profit engines are losing steam
Cisco’s stock price of $89.84 implies a valuation ratio of 20.5x forward P/E. Read our free research report to see why you should think twice about including CSCO in your portfolio.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.